Cover Image
市場調查報告書

胃腸道基質腫瘤 (GIST):開發中產品分析

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229743
出版日期 內容資訊 英文 210 Pages
訂單完成後即時交付
價格
Back to Top
胃腸道基質腫瘤 (GIST):開發中產品分析 Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 210 Pages
簡介

所謂胃腸道基質瘤(GIST)是指消化道上產生的一種腫瘤。屬於軟組織瘤的一群,同時有良性與惡性。主要的症狀有腹部的疼痛和不適、手觸壓可感覺到腹部的腫塊、噁心·嘔吐、吐血、含血糞便、伴隨頭痛的倦怠感(紅血球不足)等。主要的治療方法包含外科手術和放射治療,標靶治療,化療等。

本報告提供全球各國治療胃腸道基質腫瘤 (GIST) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

胃腸道基質腫瘤 (GIST)概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

胃腸道基質腫瘤 (GIST):企業開發中的治療藥

胃腸道基質腫瘤 (GIST):大學/機關研究中的治療藥

胃腸道基質腫瘤 (GIST):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

胃腸道基質腫瘤 (GIST):企業開發中的產品

胃腸道基質腫瘤 (GIST):大學/機關研究中的產品

胃腸道基質腫瘤 (GIST的)治療藥的開發企業

  • AB Science SA
  • Advenchen Laboratories, LLC
  • Ariad Pharmaceuticals, Inc.
  • Arog Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Blueprint Medicines Corporation
  • Boston Biomedical, Inc.
  • Calithera Biosciences, Inc.
  • Chipscreen Biosciences Ltd
  • Deciphera Pharmaceuticals, LLC
  • F. Hoffmann-La Roche Ltd.
  • Horizon Pharma Plc
  • Immunicum AB
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Kolltan Pharmaceuticals, Inc.
  • Natco Pharma Limited
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • Omeros Corporation
  • Plexxikon Inc.
  • TG Therapeutics, Inc.
  • Threshold Pharmaceuticals, Inc.

胃腸道基質腫瘤 (GIST):治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

胃腸道基質腫瘤 (GIST):最近的開發平台趨勢

胃腸道基質腫瘤 (GIST):暫停中的計劃

胃腸道基質腫瘤 (GIST):開發中止的產品

胃腸道基質腫瘤 (GIST):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8645IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor - Pipeline Review, H2 2016, provides an overview of the Gastrointestinal Stromal Tumor (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 15, 10, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.Gastrointestinal Stromal Tumor.

Gastrointestinal Stromal Tumor (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastrointestinal Stromal Tumor (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastrointestinal Stromal Tumor (GIST) Overview
  • Therapeutics Development
    • Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview
    • Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis
  • Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies
  • Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies
  • Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes
  • Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development
    • AB Science SA
    • Advanced Accelerator Applications S.A.
    • Advenchen Laboratories, LLC
    • Ariad Pharmaceuticals, Inc.
    • Arog Pharmaceuticals, Inc.
    • ArQule, Inc.
    • Array BioPharma Inc.
    • Astex Pharmaceuticals Inc
    • Blueprint Medicines Corporation
    • Boston Biomedical, Inc.
    • Calithera Biosciences, Inc.
    • Chipscreen Biosciences Ltd
    • Daiichi Sankyo Company, Limited
    • Deciphera Pharmaceuticals, LLC
    • F. Hoffmann-La Roche Ltd.
    • Horizon Pharma Plc
    • Immunicum AB
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Kolltan Pharmaceuticals, Inc.
    • Natco Pharma Limited
    • Nerviano Medical Sciences S.r.l.
    • Novartis AG
    • Omeros Corporation
    • Plexxikon Inc.
    • Rhizen Pharmaceuticals S.A.
    • Taiho Pharmaceutical Co., Ltd.
  • Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alpelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amcasertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • apatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARQ-092 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • binimetinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLU-285 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • buparlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-839 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CHMFLKIT-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crenolanib besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-2164 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCC-2618 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • infigratinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon gamma-1b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Intuvax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KTN-0158 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nilotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMSP-088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRCAN-019 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onalespib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Antagonize GRPR for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pexidartinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-9486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ponatinib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF-1126 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHR-1020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-116 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TGR-1202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vemurafenib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gastrointestinal Stromal Tumor (GIST) - Dormant Projects
  • Gastrointestinal Stromal Tumor (GIST) - Discontinued Products
  • Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
      • Jul 13, 2016: Boston Biomedical Announces Generic Name of BBI-503: Amcasertib
      • May 24, 2016: Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2016 American Society of Clinical Oncology Annual Meeting
      • Apr 20, 2016: Kolltan Pharmaceuticals Announces Presentations of Anti-KIT Antibody Preclinical Data at the 2016 American Association for Cancer Research Annual Meeting
      • Jul 13, 2015: Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for BLU-285
      • Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets
      • Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting
      • Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors
      • Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Masican
      • Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig
      • Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors
      • Apr 09, 2013: Ariad Pharma Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations In Oncogenic Driver Of Gastrointestinal Stromal Tumors
      • Mar 20, 2013: Ariad Pharma Announces Presentations Of Preclinical Data On Iclusig At AACR Annual Meeting
      • Oct 04, 2012: AB Science Announces Acceptance Of Marketing Application For Masitinib By EMA To Treat Gleevec-resistant Gastro-intestinal Stromal Tumor
      • Feb 01, 2012: AB Science Reports Encouraging Results From Phase II Study With Its Investigational Drug, Masitinib
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2016
  • Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications S.A., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories, LLC, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals, Inc., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule, Inc., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corporation, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical, Inc., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences, Inc., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Limited, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corporation, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2016
  • Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2016
  • Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top